This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2020 Mar;158(4):806-811.

doi: 10.1053/j.gastro.2019.12.051. Epub 2020 Jan 21.

Precision Therapy in RAS Mutant Colorectal Cancer

Rodrigo Dienstmann¹, Kate Connor², Annette T Byrne²; COLOSSUS Consortium

Collaborators, Affiliations

Collaborators

COLOSSUS Consortium:
W H Fridman, D Lambrechts, A Sadanandam, L Trusolino, J H M Prehn, J Tabernero, W Kolch

Affiliations

¹ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² Royal College of Surgeons in Ireland, Dept of Physiology and Medical Physics, RCSI Centre for Systems Medicine, Dublin 2, Ireland.

PMID: 31972237
DOI: 10.1053/j.gastro.2019.12.051

Editorial

Precision Therapy in RAS Mutant Colorectal Cancer

Rodrigo Dienstmann et al. Gastroenterology. 2020 Mar.

. 2020 Mar;158(4):806-811.

doi: 10.1053/j.gastro.2019.12.051. Epub 2020 Jan 21.

Authors

Rodrigo Dienstmann¹, Kate Connor², Annette T Byrne²; COLOSSUS Consortium

Collaborators

COLOSSUS Consortium:
W H Fridman, D Lambrechts, A Sadanandam, L Trusolino, J H M Prehn, J Tabernero, W Kolch

Affiliations

¹ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² Royal College of Surgeons in Ireland, Dept of Physiology and Medical Physics, RCSI Centre for Systems Medicine, Dublin 2, Ireland.

PMID: 31972237
DOI: 10.1053/j.gastro.2019.12.051

No abstract available

PubMed Disclaimer

Similar articles

The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
Ushijima T, Yoshino T. Ushijima T, et al. Cancer Res. 2016 Nov 15;76(22):6443-6444. doi: 10.1158/0008-5472.CAN-16-2867. Cancer Res. 2016. PMID: 28148677 No abstract available.
Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Grothey A, Sargent DJ. Grothey A, et al. JAMA Oncol. 2016 Sep 1;2(9):1133-4. doi: 10.1001/jamaoncol.2016.2304. JAMA Oncol. 2016. PMID: 27273467 No abstract available.
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA. Queralt B, et al. Oncotarget. 2016 Dec 13;7(50):82185-82199. doi: 10.18632/oncotarget.11985. Oncotarget. 2016. PMID: 27636997 Free PMC article.
Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A, Hassanian SM, ShahidSales S, Farjami Z, Hasanzadeh M, Anvari K, Aledavood A, Maftouh M, Ferns GA, Khazaei M, Avan A. Bahrami A, et al. J Cell Physiol. 2018 Mar;233(3):2058-2066. doi: 10.1002/jcp.25890. Epub 2017 May 23. J Cell Physiol. 2018. PMID: 28262927 Review.
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS, Semrad TJ. Lin PS, et al. Methods Mol Biol. 2018;1765:281-297. doi: 10.1007/978-1-4939-7765-9_18. Methods Mol Biol. 2018. PMID: 29589315 Review.

See all similar articles

Cited by

Strategies to tackle RAS-mutated metastatic colorectal cancer.
Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Patelli G, et al. ESMO Open. 2021 Jun;6(3):100156. doi: 10.1016/j.esmoop.2021.100156. Epub 2021 May 25. ESMO Open. 2021. PMID: 34044286 Free PMC article. Review.
Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.
Liu P, Jiao F, Zhang Z, Zhao F, Cai J, Chen S, Fu T, Li M. Liu P, et al. Am J Cancer Res. 2022 Nov 15;12(11):5300-5314. eCollection 2022. Am J Cancer Res. 2022. PMID: 36504908 Free PMC article.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Cardone C, et al. ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603521 Free PMC article. Clinical Trial.
Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.
Zheng Y, Peng H, Hu X, Ou Y, Wang D, Wang H, Ren S. Zheng Y, et al. Front Pharmacol. 2023 May 30;14:1199395. doi: 10.3389/fphar.2023.1199395. eCollection 2023. Front Pharmacol. 2023. PMID: 37324454 Free PMC article.
Combining KRAS gene status with preoperative D‑dimer levels as a predictive marker of venous thromboembolism risk in patients with resectable colorectal cancer: A prospective cohort study.
Xu D, He Y, Liao C, Tan J. Xu D, et al. Biomed Rep. 2024 Apr 22;20(6):96. doi: 10.3892/br.2024.1784. eCollection 2024 Jun. Biomed Rep. 2024. PMID: 38765860 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal